November 05, 2008
Gilead Sciences to Present at Three Upcoming Investor Conferences
Rodman & Renshaw 10th Annual Healthcare Conference on November
Deutsche Bank 2008 DB-Biotech Boston Confab on November 11th
17th Annual Credit Suisse Healthcare Conference on November 12th
Webcasts Available Through Gilead Corporate Website
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 5, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the company will be webcasting its corporate presentation at three upcoming investor conferences: Rodman & Renshaw 10th Annual Healthcare Conference in New York, Deutsche Bank 2008 DB-Biotech Boston Confab in Boston and the 17th Annual Credit Suisse Healthcare Conference in Phoenix. These webcasts may be accessed via the company's corporate website at www.gilead.com.
Kevin Young, Gilead's Executive Vice President of Commercial Operations, will provide an overview of the company at both the Rodman & Renshaw conference on Monday, November 10 at 12:00 p.m. Eastern Standard Time (EST) and at the Deutsche Bank Confab on Tuesday, November 11 at 10:15 a.m. EST.
John F. Milligan, PhD, Gilead's President and Chief Operating Officer, will provide an overview of the company at the Credit Suisse Healthcare Conference on Wednesday, November 12 at 11:30 a.m. Mountain Standard Time (1:30 p.m. EST).
To access the live webcasts via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to each live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
CONTACT: Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936
SOURCE: Gilead Sciences, Inc.